Customize
Quick Links
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This activity has been approved for 1.5 AMA PRA Category 1 Credits™.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Bristol-Myers Squibb.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

CFS: Medical Crossfire®: Evaluating Immuno-Oncology Strategies Across Tumor Types

CFS: Medical Crossfire®: Evaluating Immuno-Oncology Strategies Across Tumor Types


Thursday, November 8, 2018
2:00 PM - 3:30 PM

Registration: 1:30 PM - 2:00 PM

New York Marriott Marquis
Julliard Complex (5th Floor)
1535 Broadway
New York, NY 10036
(212) 398-1900

Overview:

Immune checkpoint inhibitors represent an entirely new treatment modality in the fight against cancer. These therapies, which harness the body’s own immune system to eradicate tumor cells, are transforming outcomes across an increasingly broad range of malignancies, and making long-term survival a reality, where until recently prognoses were poor.

In order to help you gain a better understanding of the mechanisms of action of these new therapies, and remain apprised of emerging evidence across tumor types so that you can appropriately integrate these agents into the management of your patients and improve outcomes, we have developed a dynamic Medical Crossfire® program to share the perspectives of leading clinical experts on the latest data and factors that may change your clinical practice. This exchange of ideas will explore the integration of immune checkpoint inhibitors into treatment algorithms for relevant malignancies, provide insights regarding the evolution of biomarkers for tailoring patient selection, and discuss the management of class-specific adverse events, giving you the opportunity to assess the opinions of multidisciplinary experts and optimize your approach to applying the evidence to real-world clinical scenarios.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Bristol-Myers Squibb.

Target Audience

This educational activity is intended for medical oncologists, hematologists, and fellows who treat patients with cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of cancer are also invited to participate.

Learning Objectives

Upon completion of this activity, participants should be better prepared to:

  1. Describe the changing role of immunotherapies for cancer management in the context of mechanistic characteristics and logical combination approaches
  2. Relate findings from clinical trials with immunotherapies across multiple lines of therapy and tumor types, as well as key ongoing clinical trials in the field
  3. Recognize evolving roles for biomarkers in the context of applying immunotherapeutic approaches to the treatment of cancer
  4. Describe appropriate strategies for management and mitigation of both rarely and commonly encountered adverse events from immunotherapies

Activity Chair

Toni K. Choueiri, MD
Director, Lank Center for Genitourinary Oncology
Director, Kidney Cancer Center
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, MA







Become a Member

Forgot Password?
Filter By